191 related articles for article (PubMed ID: 20670946)
1. Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts.
Zhao WM; Wang L; Park H; Chhim S; Tanphanich M; Yashiro M; Kim KJ
Clin Cancer Res; 2010 Dec; 16(23):5750-8. PubMed ID: 20670946
[TBL] [Abstract][Full Text] [Related]
2. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.
Wang L; Park H; Chhim S; Ding Y; Jiang W; Queen C; Kim KJ
Mol Cancer Ther; 2012 Apr; 11(4):864-72. PubMed ID: 22351746
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells.
Matsuda Y; Hagio M; Seya T; Ishiwata T
Mol Cancer Ther; 2012 Sep; 11(9):2010-20. PubMed ID: 22778155
[TBL] [Abstract][Full Text] [Related]
4. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
[TBL] [Abstract][Full Text] [Related]
5. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
6. Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity.
Yin Y; Djakovic S; Marsters S; Tien J; Peng J; Tremayne J; Lee G; Neve RM; Wu Y; Merchant M; Ashkenazi A; Carter PJ
Mol Cancer Ther; 2015 Oct; 14(10):2270-8. PubMed ID: 26269606
[TBL] [Abstract][Full Text] [Related]
7. Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer.
Yashiro M; Kuroda K; Masuda G; Okuno T; Miki Y; Yamamoto Y; Sera T; Sugimoto A; Kushiyama S; Nishimura S; Togano S; Ohira M
Sci Rep; 2021 Feb; 11(1):4698. PubMed ID: 33633310
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Sommer A; Kopitz C; Schatz CA; Nising CF; Mahlert C; Lerchen HG; Stelte-Ludwig B; Hammer S; Greven S; Schuhmacher J; Braun M; Zierz R; Wittemer-Rump S; Harrenga A; Dittmer F; Reetz F; Apeler H; Jautelat R; Huynh H; Ziegelbauer K; Kreft B
Cancer Res; 2016 Nov; 76(21):6331-6339. PubMed ID: 27543601
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14.
Okuno T; Yashiro M; Masuda G; Togano S; Kuroda K; Miki Y; Hirakawa K; Ohsawa M; Wanibuchi H; Ohira M
Ann Surg Oncol; 2019 Apr; 26(4):1093-1102. PubMed ID: 30652228
[TBL] [Abstract][Full Text] [Related]
11. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
12. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Takeda M; Arao T; Yokote H; Komatsu T; Yanagihara K; Sasaki H; Yamada Y; Tamura T; Fukuoka K; Kimura H; Saijo N; Nishio K
Clin Cancer Res; 2007 May; 13(10):3051-7. PubMed ID: 17505008
[TBL] [Abstract][Full Text] [Related]
13. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
[TBL] [Abstract][Full Text] [Related]
14. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
[TBL] [Abstract][Full Text] [Related]
15. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
16. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
[TBL] [Abstract][Full Text] [Related]
17. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
Kunii K; Davis L; Gorenstein J; Hatch H; Yashiro M; Di Bacco A; Elbi C; Lutterbach B
Cancer Res; 2008 Apr; 68(7):2340-8. PubMed ID: 18381441
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
[TBL] [Abstract][Full Text] [Related]
19. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
20. FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1.
Huang T; Wang L; Liu D; Li P; Xiong H; Zhuang L; Sun L; Yuan X; Qiu H
Int J Oncol; 2017 May; 50(5):1501-1512. PubMed ID: 28339036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
